Your browser doesn't support javascript.
loading
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan, Jing; Tan, Yue; Wang, Guoling; Deng, Biping; Ling, Zhuojun; Song, Weiliang; Seery, Samuel; Zhang, Yanlei; Peng, Shuixiu; Xu, Jinlong; Duan, Jiajia; Wang, Zelin; Yu, Xinjian; Zheng, Qinlong; Xu, Xiuwen; Yuan, Ying; Yan, Fangrong; Tian, Zhenglong; Tang, Kaiting; Zhang, Jiecheng; Chang, Alex H; Feng, Xiaoming.
Afiliação
  • Pan J; State Key Laboratory of Experimental Hematology, Boren Clinical Translational Center, Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Tan Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin China.
  • Wang G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin China.
  • Deng B; Cytology Laboratory, Beijing Boren Hospital, Beijing, China.
  • Ling Z; Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Song W; Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Seery S; School of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang Y; Faculty of Health and Medicine, Division of Health Research, Lancaster University, Lancaster, United Kingdom.
  • Peng S; Shanghai YaKe Biotechnology Ltd, Shanghai, China.
  • Xu J; Shanghai YaKe Biotechnology Ltd, Shanghai, China.
  • Duan J; Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Wang Z; Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Yu X; Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Zheng Q; Medical Laboratory, Beijing Boren Hospital, Beijing, China.
  • Xu X; Medical Laboratory, Beijing Boren Hospital, Beijing, China.
  • Yuan Y; Medical Laboratory, Beijing Boren Hospital, Beijing, China.
  • Yan F; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, TX.
  • Tian Z; Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Longmian Avenue, Nanjing, China.
  • Tang K; Gobroad Research Center, Gobroad Medical Group, Beijing, China.
  • Zhang J; Department of Hematology, Beijing Boren Hospital, Beijing, China.
  • Chang AH; Department of Hospital Management, Gobroad Medical Group, Beijing, China.
  • Feng X; Shanghai YaKe Biotechnology Ltd, Shanghai, China.
J Clin Oncol ; 39(30): 3340-3351, 2021 10 20.
Article em En | MEDLINE | ID: mdl-34324392
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Antígenos CD7 / Leucemia-Linfoma Linfoblástico de Células T Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Etiology_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: J Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Antígenos CD7 / Leucemia-Linfoma Linfoblástico de Células T Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Etiology_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: J Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China